Nonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring System Patents (Class 514/81)
-
Publication number: 20140323416Abstract: The aspects of the present disclosure are directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient. In particular, to 5-methyldihydromorphone prodrug compounds described in general Formula I and II and the use of the compounds for treating pain associated with a variety of chronic human disorders including for example neuropathic pain and pain associated with cancer, surgeries or injuries.Type: ApplicationFiled: April 16, 2014Publication date: October 30, 2014Inventors: Anthony MARFAT, Peter CORNELIUS, Robert VOLKMANN, Panayiotis ZAGOURAS, Frederick Raymond NELSON, Anton Franz Joseph FLIRI
-
Publication number: 20140315862Abstract: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.Type: ApplicationFiled: March 14, 2014Publication date: October 23, 2014Applicant: Sarepta Therapeutics, Inc.Inventor: Edward M. Kaye
-
Publication number: 20140308243Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—Z—W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 16, 2014Publication date: October 16, 2014Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Hui Cao, Xiaowen Peng, Zhigang Chen, Yat Sun Or
-
Publication number: 20140309191Abstract: In part, the present invention is directed to antibacterial compounds and salts thereof.Type: ApplicationFiled: November 8, 2013Publication date: October 16, 2014Applicant: Affinium Pharmaceuticals, Inc.Inventors: Henry Pauls, Jailall Ramnauth
-
Patent number: 8859529Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.Type: GrantFiled: September 22, 2009Date of Patent: October 14, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Ling Tong, Michael K. C. Wong, Brian J. Lavey, Joseph A. Kozlowski, Lei Chen, Razia K. Rizvi, Aneta Maria Kosinski, De-Yi Yang, Guowei Zhou, Kristen E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
-
Publication number: 20140303074Abstract: The present disclosure provides methods of reducing immunodeficiency virus transcription, involving use of diflunisal or an active ester thereof. The disclosure also provides methods of treating an immunodeficiency virus infection in an individual, the method generally involving administering to the individual an effective amount of diflunisal or an active ester thereof.Type: ApplicationFiled: December 12, 2012Publication date: October 9, 2014Inventors: Eric M. Verdin, Kotaro Shirakawa
-
Publication number: 20140303121Abstract: Heterocyclic compounds of formula (I), methods for their preparation, pharmaceutical compositions containing such a compound and their therapeutic uses.Type: ApplicationFiled: March 14, 2014Publication date: October 9, 2014Inventors: Jiazhong Zhang, Wayne Spevak
-
Publication number: 20140303073Abstract: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.Type: ApplicationFiled: April 11, 2014Publication date: October 9, 2014Applicant: Sarepta Therapeutics, Inc.Inventor: Patrick L. Iversen
-
Publication number: 20140296177Abstract: A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple Staphylococcus aureus isolates, including clinically important methicillin-resistant S. aureus (MRSA) are disclosed that are non-toxic.Type: ApplicationFiled: September 21, 2012Publication date: October 2, 2014Inventors: Andrew Abel, Steven Polyak, Grant Booker, John Wallace, Tatiana Soares Da Costa, Angie Jarrad, William Tieu, Kelly Lee Keeling, Daniel Sejer Pederson, Nicole Pendini, Matthew Wilce, Min Yin Yap
-
Patent number: 8846643Abstract: There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.Type: GrantFiled: October 11, 2012Date of Patent: September 30, 2014Assignee: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
-
Patent number: 8841310Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.Type: GrantFiled: October 7, 2009Date of Patent: September 23, 2014Assignee: Janssen R & D IrelandInventor: Paul Stoffels
-
Publication number: 20140274959Abstract: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: The Regents of the University of California, a California corporationInventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
-
Publication number: 20140255426Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV).Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Applicants: EMORY UNIVERSITY, Children's Healthcare of Atlanta, Inc., The General Hospital CorporationInventors: Guido Silvestri, Ann M. Chahroudi, Mathias Lichterfeld, Maria Jose Buzon, Raymond F. Schinazi
-
Publication number: 20140255339Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicants: Idenix Pharmaceuticals, Inc., Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Jean-Pierre SOMMADOSSI, Gilles GOSSELIN, Claire PIERRA, Christian PERIGAUD, Suzanne PEYROTTES
-
Patent number: 8822434Abstract: Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogs of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogs significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogs for treatment of heart failure has been expanded.Type: GrantFiled: February 22, 2011Date of Patent: September 2, 2014Assignees: The University of Connecticut, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Bruce Liang, Kenneth A. Jacobson, Bhalchandra V. Joshi, Thatikonda Santhosh Kumar
-
Publication number: 20140243288Abstract: The present invention relates to a fused ring-containing oxazolidinone compound shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, A, B and C are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound for the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases.Type: ApplicationFiled: September 29, 2012Publication date: August 28, 2014Inventors: Hui Zhang, Aichen Wang
-
Publication number: 20140235581Abstract: Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.Type: ApplicationFiled: August 7, 2012Publication date: August 21, 2014Applicant: JW PHARMACEUTICAL CORPORATIONInventors: Joo-Young Cha, Kwan-Hoo Lee, Ji-Eun Jung
-
Publication number: 20140235582Abstract: Compounds of Formula (I) wherein B is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Y is a linker moiety selected from the group consisting of a direct bond. R, R1, R2, and R3 are each individually selected from the group consisting substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heterocycle.Type: ApplicationFiled: August 27, 2012Publication date: August 21, 2014Applicants: Sanford-Burnham Medical Research Institute, Southern Research InstituteInventors: Marintha L. Heil, Nicholas D.P. Cosford, Nicholas Pagano, Peter Teriete
-
Publication number: 20140221315Abstract: The present application provides novel pyrimido-pyridazinone compounds and methods for preparing and using these compounds. These compounds are useful in treating inflammation in patients by administering one or more of the compounds to a patient. In one embodiment, the novel pyrimido-pyridazinone compound is of Formula (I) and R1 and R2 are defined herein.Type: ApplicationFiled: April 3, 2014Publication date: August 7, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Aranapakam Venkatesan, Roger Astbury Smith, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Vishnu Basetti, Karunasree Kunta
-
Publication number: 20140213553Abstract: This invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV integrase inhibitor.Type: ApplicationFiled: May 3, 2012Publication date: July 31, 2014Applicant: CONCERT PHARMACEUTICALS INC.Inventor: Adam Morgan
-
Publication number: 20140213554Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.Type: ApplicationFiled: December 20, 2013Publication date: July 31, 2014Inventors: Guoxian Wu, Katrina Chan, Todd Ewing, Prabha N. Ibrahim, Jack Lin, Marika Nespi, Wayne Spevak, Ying Zhang
-
Publication number: 20140213556Abstract: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (?)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.Type: ApplicationFiled: March 27, 2014Publication date: July 31, 2014Applicant: GILEAD SCIENCES, INC.Inventors: Terrence C. DAHL, Mark M. MENNING, Reza OLlYAI
-
Publication number: 20140213555Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.Type: ApplicationFiled: January 24, 2014Publication date: July 31, 2014Applicant: Rigel Pharmaceuticals, Inc.Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
-
Publication number: 20140205567Abstract: The present invention discloses a class of novel macro-heterocyclic compounds represented by the formula Ia or Ib, and their intermediates, preparation methods and the uses. The macro-heterocyclic compounds of the present invention have good inhibitory activities against hepatitis C virus (HCV), and can be used to treat HCV infection effectively by its excellent inhibition against HCV, low toxicity and side effects.Type: ApplicationFiled: June 14, 2012Publication date: July 24, 2014Applicant: AB Pharma Ltd.Inventor: Zheng-yun James Zhan
-
Publication number: 20140206650Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Inventors: Blaise S. Lippa, Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Chester A. Metcalf, III, Andrew J. Jackson
-
Publication number: 20140193491Abstract: The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medicine, particularly for the prophylaxis and/or treatment of diseases caused by retroviruses.Type: ApplicationFiled: May 30, 2012Publication date: July 10, 2014Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Patent number: 8770201Abstract: Condoms having an elastomeric layer and coating containing an anhydrous warming lubricant and at least one or more ingredients dispersed therein, the coating being disposed on one or both surfaces are provided. The ingredients disposed on the elastomeric layer can be solid particles or encapsulated ingredients that are insoluble in the anhydrous warming lubricant and soluble in water. Methods of producing and using these condoms are also provided.Type: GrantFiled: October 23, 2008Date of Patent: July 8, 2014Assignee: GlycoBioSciences Inc.Inventors: Michael S. Zedalis, Beng Sim Chuah, David M. Lucas, Angela M. Shiokawa, Jose R. Siqueira, Dave Narasimhan
-
Patent number: 8771648Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.Type: GrantFiled: July 27, 2012Date of Patent: July 8, 2014Assignee: Rigel Pharmaceuticals, Inc.Inventors: Bindhumadhavan Gururajan, Farhan Abdul Karim Alhusban, Ian Paul Gabbott, David Bradley Brook Simpson, Dawn Sievwright
-
Patent number: 8765722Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: GrantFiled: June 26, 2013Date of Patent: July 1, 2014Assignee: Gilead Sciences, Inc.Inventors: Aesop Cho, Lee S. Chong, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Choung U. Kim, Qi Liu, William J. Watkins, Jennifer R. Zhang
-
Publication number: 20140179632Abstract: This invention relates to methods for inhibiting kinase activity and/or inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an ophthalmic disease, condition or disorder treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions comprising administering novel compounds that inhibit protein tyrosine kinase activity.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: MethylGene Inc.Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
-
Publication number: 20140179633Abstract: Disclosed is a composition including a pyrazino-triazine derivative and a pharmaceutically acceptable salt thereof. The composition includes a solubilizer or a stabilizer and thus can exhibit very excellent solubility and stability.Type: ApplicationFiled: August 24, 2012Publication date: June 26, 2014Applicant: JW PHARMACEUTICAL CORPORATIONInventors: Min-Seok Choi, Young-Hoon Kim
-
Patent number: 8758786Abstract: The present invention relates to human metabolism, in particular fat reduction and a cosmetic and pharmaceutical formulation, as well as respective uses in particular together with a dressing material according to the invention.Type: GrantFiled: August 28, 2007Date of Patent: June 24, 2014Inventor: Gerard Hassler
-
Patent number: 8754065Abstract: A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).Type: GrantFiled: August 15, 2012Date of Patent: June 17, 2014Assignee: Gilead Sciences, Inc.Inventors: Dazhan Liu, Bing Shi, Fang Wang, Richard Hung Chiu Yu
-
Publication number: 20140162985Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: September 6, 2013Publication date: June 12, 2014Applicant: ABBVIE INC.Inventors: Andrew Burchat, Thomas D. Gordon, Kelly D. Mullen, David C. Ihle, Michael J. Morytko, Kevin P. Cusack, Gloria Y. Lo Schiavo, Lei Wang, Michael Friedman
-
Publication number: 20140155813Abstract: To provide a technology for introducing a PMO with remarkably enhanced cell permeability, leading to significantly enhanced introduction efficiency to thereby provide a therapeutic drug that dramatically ameliorates a medical condition of DMD. Also provided is a therapeutic drug for Duchenne muscular dystrophy, including as an active ingredient a Bubble liposome having a specific morpholino oligomer (PMO) bound to a surface thereof, in which the PMO is introduced into a muscle fiber (muscle cell) of a muscle tissue with high efficiency by administration of the therapeutic drug into the muscle tissue or into a blood vessel followed by ultrasound irradiation to the muscle tissue transcutaneously.Type: ApplicationFiled: April 25, 2012Publication date: June 5, 2014Applicant: NEPA GENE CO., LTD.Inventors: Yoichi Negishi, Yoko Takahashi, Kazuo Maruyama, Yukihiko Aramaki
-
Publication number: 20140154240Abstract: The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.Type: ApplicationFiled: May 30, 2013Publication date: June 5, 2014Inventors: Kerim Babaoglu, Constantine G. Boojamra, Eugene J. Eisenberg, Hon Chung Hui, Richard L. Mackman, Jay P. Parrish, Michael Sangi, Oliver L. Saunders, Dustin Siegel, David Sperandio, Hai Yang
-
Publication number: 20140148410Abstract: Disclosed are nucleopeptide compounds that include a nucleobase, and an amino acid. Certain compounds further comprise a glycoside. The compounds may self-assemble to form supramolecular hydrogels. Also, the compounds may be used as a platform to examine specific biological functions (e.g., binding to DNA and RNA) of a dynamic supramolecular system that is able to interact with both proteins and nucleic acids. Other uses include: methods of growing cells and methods of delivering a substance to a cell.Type: ApplicationFiled: December 2, 2013Publication date: May 29, 2014Applicant: Brandeis UniversityInventor: Bing Xu
-
Publication number: 20140134246Abstract: Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: Aptalis Pharmatech, Inc.Inventors: Gopi VENKATESH, Vijaya SWAMINATHAN, Jin-Wang LAI
-
Publication number: 20140128347Abstract: An oligonucleotide derivative comprises repeating structural units represented by the following general formula (wherein B represents adenine, guanine, cytosine, or uracil; X represents a sulfur atom or an oxygen atom; n represents an integer of 6 to 60; and B and X are independently represented in each of the repeating structural units), wherein X is a sulfur atom in at least one of the repeating structural units represented by the general formula:Type: ApplicationFiled: June 1, 2012Publication date: May 8, 2014Inventors: Akira Matsuda, Mayumi Takahashi
-
Publication number: 20140128346Abstract: The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined herein, compositions comprising an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound.Type: ApplicationFiled: December 21, 2011Publication date: May 8, 2014Applicant: PURDUE PHARMA L.P.Inventors: Dawit Tadesse, Laykea Tafesse, Zhou Xiaoming
-
Patent number: 8716264Abstract: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (?)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.Type: GrantFiled: September 4, 2008Date of Patent: May 6, 2014Assignee: Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Mark M. Menning, Reza Oliyai
-
Publication number: 20140121185Abstract: Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.Type: ApplicationFiled: September 23, 2013Publication date: May 1, 2014Applicant: MEDICON PHARMACEUTICALS, INC.Inventor: Basil RIGAS
-
Publication number: 20140121186Abstract: The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.Type: ApplicationFiled: December 23, 2013Publication date: May 1, 2014Applicant: Chimerix, Inc.Inventors: George R. Painter, Merrick R. Almond
-
Patent number: 8710030Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.Type: GrantFiled: October 4, 2012Date of Patent: April 29, 2014Assignee: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, James R. Beadle
-
Publication number: 20140113882Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.Type: ApplicationFiled: September 27, 2013Publication date: April 24, 2014Applicants: Cancer Research Technology Limited, Cephalon, Inc.Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
-
Patent number: 8697675Abstract: A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).Type: GrantFiled: August 15, 2012Date of Patent: April 15, 2014Assignee: Gilead Sciences, Inc.Inventors: Dazhan Liu, Bing Shi, Fang Wang, Richard Hung Chiu Yu
-
Publication number: 20140100194Abstract: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.Type: ApplicationFiled: December 5, 2013Publication date: April 10, 2014Applicant: Janssen Pharmaceutica, NVInventors: Raymond W Colburn, Scott L. Dax, Christopher M. Flores, Jay M. Matthews
-
Publication number: 20140100193Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.Type: ApplicationFiled: November 25, 2013Publication date: April 10, 2014Applicant: Joyant Pharmaceuticals, Inc.Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
-
Patent number: 8685984Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: July 5, 2013Date of Patent: April 1, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein, Thomas J. Podsadecki
-
Publication number: 20140088044Abstract: The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.Type: ApplicationFiled: August 28, 2013Publication date: March 27, 2014Inventors: Basil Rigas, Jason B. Rigas